共 50 条
- [41] Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis [J]. Supportive Care in Cancer, 2020, 28 : 857 - 866
- [43] NEPA <sc>(</sc>Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial [J]. CANCER MEDICINE, 2025, 14 (07):
- [45] A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (02) : 121 - 129
- [47] Pharmacokinetics and Bioequivalence Study of a Fixed Dose Combination of Rabeprazole and Itopride in Healthy Indian Volunteers [J]. ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2009, 59 (09): : 451 - 454
- [50] Safety, tolerability and pharmacokinetic study of recombinant human parathyroid hormone [rhPTH (1-84)] in Chinese healthy volunteers [J]. Journal of Huazhong University of Science and Technology [Medical Sciences], 2009, 29 : 431 - 434